The FDA Just Handed Psychedelic Drug Sponsors a Framework. Now the Hard Part Starts.

The FDA finalized guidance for psychedelic drug clinical trials sets detailed requirements on trial environment, therapist training, and safety protocols, creating new operational and compliance challenges for sponsors. The guidance clarifies FDA expectations but does not ease DEA Schedule I registration barriers, which remain a critical bottleneck for psychedelic drug development.

This Wire brief sits within Fusion42's coverage of Health.